Premium
Immunoreactivity of the 14F7 Mab raised against N ‐Glycolyl GM 3 Ganglioside in retinoblastoma tumours
Author(s) -
Torbidoni Ana Vanesa,
Scursoni Alejandra,
Camarero Sandra,
Segatori Valeria,
Gabri Mariano,
Alonso Daniel,
Chantada Guillermo,
Dávila María Teresa G.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.12578
Subject(s) - retinoblastoma , immunohistochemistry , monoclonal antibody , ganglioside , bone marrow , pathology , antibody , cancer research , cell culture , microbiology and biotechnology , biology , medicine , immunology , gene , biochemistry , genetics
The identification of molecules expressed selectively on the surface of retinoblastoma cells would allow applying targeted therapies. The Ganglioside, N ‐Glycolyl‐ GM 3 (NeuGc‐ GM 3), is an attractive candidate, as it has been detected in other paediatric neuroectodermic tumours, and it is not expressed in human normal tissues. The 14F7 antibody recognizes specifically the ganglioside NeuGc‐ GM 3. Purpose To characterize the expression of NeuGc‐ GM 3 in retinoblastoma cell lines and in retinoblastoma tumours using the 14F7 monoclonal antibody. Methods We studied WERI ‐Rb1 and Y79 cell lines, 24 retinoblastoma primary tumours from unilateral and bilateral cases and two bone marrow biopsies from metastatic retinoblastoma. Tumours were classified into three groups: non‐invasive ( n = 13), invasive ( n = 9) and metastatic ( n = 2). Three eyes enucleated because of non‐tumoural conditions were used as controls. Cell lines and tumour sections were studied by immunohistochemistry using the 14F7 antibody. NeuGc‐ GM 3 expression was evaluated by analysing the percentage of positive tumoural cells and the staining intensity. These parameters were analysed comparatively among the three groups. Results Both retinoblastoma cell lines showed immunoreactivity to NeuGc‐ GM 3 but WERI ‐Rb1 presented higher intensity than Y79. All the tumours studied showed strong immunoreactivity to NeuGc‐ GM 3 with no significant differences among groups. In both bone marrow specimens, NeuGc‐ GM 3 immunoreactivity was observed in retinoblastoma cells. In bilaterally enucleated cases, NeuGc‐ GM 3 immunoreactivity was not altered before and after chemotherapy. Non‐tumoural retinas were negative. Conclusions NeuGc‐ GM 3 is highly expressed in retinoblastoma cell lines, tumours and metastatic cells to the bone marrow, and it is not detectable in control eyes. There were no significant differences in the immunoreactivity to 14F7 among tumours from different disease stages. Its immunoreactivity did not change after chemotherapy.